Updated date: 2026-01-07
Related Stories GLP-1 weight loss may reduce first-impression penalties in relationships and hiring Nearly one in 10 Britons use or want weight-loss medication Semaglutide fuels rapid growth in US GLP-1RA use as payments rise In comparison to composite control, GLP-1RA use exhibited a decreased risk of 34 outcomes, including pneumonia, respiratory failure, alcohol use disorders, COPD, and suicidal ideation, and an increased risk of 17 outcomes, including abdominal pain, GERD, nephrolithiasis, and sleep disturbances
10.1016/j.jhep.2022.01.009 42
J Pharmacol Exp Ther 2012;340:483-489
If you swallow the tablet, the medication will likely be destroyed by your stomach acid and will not be effective
The research is genuinely mixed: some studies have found an increased risk of NAION in semaglutide users, while other large multinational studies found no significant difference